When Erica Rogers left the vascular business in 1999, carotid artery stenting was The Next Big Thing for interventional cardiologists. It only made sense, since as many as half of all strokes are caused by a narrowing of the primary arteries that run through the neck to the head, and cardiologists had experience with a somewhat similar procedure in narrowed heart vessels.
The big question was whether carotid stenting ever would be as good as carotid endarterectomy, a surgical repair of the artery performed for much of the past 50 years.
Fast forward to 2012. Rogers had held top positions at a couple of companies, including the nonprofit drug-device company Medicines360 and Visogen, which Abbott Laboratories bought in 2009 for $400 million, when private equity firm Warburg Pincus LLC talked to Rogers about Silk Road Medical.
Read more: http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/04/silk-road-medical-carotid-artery-stent-stroke.html?page=all
|
Comments are closed.
|
Archives
November 2019
|
RSS Feed
